| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Doravirine |
| Brand | Pifeltro® |
| Indication | In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. |
| Assessment Process | |
| Rapid review commissioned | 06/12/2018 |
| Rapid review completed | 16/01/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that doravirine (Pifeltro®) not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.